Herschorn, S., Nazir, J., Ramos, B. and Hakimi, Z. (2017) “Supplementary data: Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada”, Canadian Urological Association Journal, 11(3-4), pp. E129–33. doi: 10.5489/cuaj.4617.